FDA Classifies Recall of Abiomed Automated Impella Heart Pump Controllers as Class I
On November 9, 2026, the US Food and Drug Administration classified the recall of certain Abiomed Automated Impella Controllers as a Class I recall, which is its most serious risk level. The FDA warned that using affected devices without required updates could lead to serious injury or death. Abiomed identified issues through a review of service records, including unreliable buttons, system instability during start-up, software defects, and failures to detect purge cassettes. These defects can delay therapy or cause a loss of heart support for patients. As of September 8, 2026, Abiomed had reported no serious injuries or deaths connected to the issue. Hospitals may continue using their current inventory while waiting for service to ensure uninterrupted care. Abiomed sent letters to affected facilities on September 18, 2026, to coordinate device updates, removals, and returns.
What was announced
The US Food and Drug Administration classified Abiomed's action on specific Automated Impella Controllers as a Class I recall on November 9, 2026. This updated an earlier alert issued by the agency on September 23, 2026.
Abiomed sent a notification letter to affected hospital customers on September 18, 2026. The recall covers three packaged US model numbers: 0042-0000-US, 0042-0010-US, and 0042-0040-US, restricted to specific serial numbers.
Abiomed identified the defects after reviewing servicing records. The issues require software, firmware, or hardware updates. Documented flaws include sticking buttons, software defects, system instability at start-up, and failure to detect the purge cassette during setup or replacement.
What it means
The Automated Impella Controller is the primary user interface for controlling Impella Catheters. The system monitors alarm conditions and provides circulatory support so a patient's heart has time to recover.
If devices are not updated, patients could experience delayed therapy or inadequate heart support. Sticking buttons can prevent staff from selecting or confirming menu choices and could cause a loss of console control.
The FDA noted that hospitals may continue using their current inventory while waiting for service from Abiomed. This instruction aims to keep patient care continuous. Abiomed service representatives will contact facilities to coordinate removing, updating, and returning machines. No serious injuries or deaths had been reported from this issue as of September 8, 2026.
What the announcement does not tell us
The notice does not state how many individual controller units are affected nationwide. It does not provide a deadline or timeline for when Abiomed will finish updating all inventory.
Additionally, the announcement does not explain why updates were not applied consistently across all controllers before the recall. It also does not explain why the servicing record review occurred when it did.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
Abiomed is removing certain Impella Controllers with various hardware, firmware, and/or software updates based on a retrospective review of servicing records.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
- Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen12 November 2026
- Early Alert: Intersurgical Inc. Removes 22mm Smoothbore breathing tubes and systems10 November 2026
- Early Alert: Arrow International Removes Products Containing Spring Wire Guide Components10 November 2026
- Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter9 November 2026
- MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication9 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.